渡航者向けデング熱ワクチンの世界市場

VacZine Analyticsが発行した調査報告書(VACZ712008)
◆英語タイトル:MarketVIEW: Dengue traveler vaccines
◆商品コード:VACZ712008
◆発行会社(リサーチ会社):VacZine Analytics
◆発行日:2017年7月
◆ページ数:※お問い合わせください。
◆レポート形式:英語 / PDF、Excel
◆納品方法:Eメール
◆調査対象地域:グローバル
◆産業分野:製薬
◆販売価格オプション(消費税別)
Executive Presentation (PDF)USD5,595 ⇒換算¥632,235見積依頼/購入/質問フォーム
PDF+ExcelUSD7,995 ⇒換算¥903,435見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はVacZine Analytics社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。VacZine Analytics社の概要及び新刊レポートはこちらでご確認いただけます。

【レポートの概要】

Dengue Fever (DF) is a mosquito-borne disease (Aedes) caused by single strand RNA viruses of the family flaviviridae. It is is currently the second most common specific etiologic diagnosis among returned travelers with febrile illness after malaria globally. It is the most common febrile illness among travelers returning from Southeast Asia and South Central Asia. The disease not only poses a risk to the health of the individual traveler but is also a public health problem as returning viraemic travelers contribute to the spread of the disease. Dengue importation into vector infected areas has caused large numbers of autochthonous cases in the EU, notably 2000 cases in Madeira, Portugal 2012-13.
Increasing trends and attack rates of dengue infection seen in travelers would justify the need for a dengue vaccine in this target group. The 3 dose (0, 6 & 12 mos) Sanofi Pasteur vaccine (CYD-TDV, Dengvaxia) has been licensed since 2015 for the prevention of disease caused by all four dengue virus serotypes in preadolescents, adolescents and adults, 9 to 45 years of age living in endemic areas. However, it has several drawbacks as a travel vaccine, mainly its long administration schedule.

This MarketVIEW product consists of a detailed Executive presentation (~80 slides) and comprehensive MS-Excel work books which forecast the potential commercial value of dengue fever vaccine(s) by competitor in travelers to 2030 from major Western points of origin to 85 countries with ongoing transmission. The model(s) contain value ($ m) and volume (mio doses) predictions in different types of traveler e.g. Vacation and Visiting Friends/Family and Business + Other in both first time and repeat/experienced individuals per region*. Detailed discussion is provided with regard to the comparative suitability of Dengvaxia, DenVAX (TAK-003), TetraVAX and TDENV-PIV to serve the travelers segment and respective product forecasts are included to 2030

【レポートの目次】

Table of Contents
Executive summary
Authors note
Commercial model – Key outputs
Dengue vaccines: forecast revenues ($ 000s) – all travelers to 2030
Dengue vaccines: forecast revenues ($ 000s) – vacation/VFR to 2030
Dengue vaccines: forecast revenues ($ 000s) – business to 2030
1st time: vacation/VFR travelers market by product ($000s) to 2030
Repeat time: vacation/VFR travelers market by product ($000s) to 2030
1st time: business travelers market by product ($000s) to 2030
Repeat time: business travelers market by product ($000s) to 2030
Revenues per competitor per traveler type, 2025 ($ 000s)
Uptake sensitivity analysis – 2025
Analysis of outbound trips data
Outbound trips to all dengue countries from Western countries* point of origin to 2035
Outbound trips to countries (ongoing transmission) from Western region* point of origin to 2035
Top 20 dengue destination countries (ongoing transmission) from USA point of origin to 2035
Trips from major Western markets to top 10 dengue countries, 2016
Outbound trips to Saudi Arabia from Western region* point of origin to 2035
Dengue in travelers: disease background and epidemiology
Factors contributing to the global increase of dengue
Dengue – incidence in travelers
Prospective studies quantifying dengue incidence in travelers
Dengue: traveler importation and spread of disease
Dengue imported cases: EU 2012-2014 [TropNet data] Imported dengue cases* by WHO region 2012-2014 [TropNet] Dengue imported cases: EU 2012-2014 by serotype [TropNet data] Aedes aegypti: current known EU distribution – April 2017
Aedes albopictus: current known EU distribution – April 2017
Dengue imported cases: United States
Areas vulnerable to dengue and outbreaks in the US 1980-2010
Serologically confirmed US DEN cases 2001-2014
Dengue imported cases: Japan
Dengue imported cases: South Korea
Dengue imported cases: Australia
Australia: Notifications of dengue virus infection 2007 to 2013
Overseas acquired cases of dengue virus infection, Australia, 2012-13, by serotype and country of acquisition
Considerations for a dengue travel vaccine
The need for a dengue travel vaccine
Main drawbacks of Dengvaxia (Sanofi Pasteur) as a travel vaccine
The ideal dengue travel vaccine: target product profile [4 slides] 2 Model contents available on request (.xls) 2 Presentation titles may apply to more than one slide (.pdf form only)

Dengue vaccine: schedule considerations for travelers segment
Dengue vaccines - competitive landscape: major players
Dengue vaccines - competitive landscape (other clinical)
Which dengue vaccine most meets traveler criteria? [3 slides]
Commercial model: methodology and assumptions
Western travelers: modelling methodology
Countries with documented ongoing dengue transmission
Countries with sporadic/uncertain dengue transmission
US Travelers 2015: profile and pre-travel behaviours
Travelers to dengue countries: model flow (US example)
Projected launch dates of dengue travel vaccines
Dengvaxia: commercial model assumptions
TAK003: commercial model assumptions
TetraVAX: commercial model assumptions
TDEN-PIV: commercial model assumptions
Dengvaxia: market share assumptions
TAK003: market share assumptions
TetraVAX: market share assumptions
TDEN-PIV: market share assumptions
Western travelers: model pricing assumptions
Immunocompromised travelers
Model caveats and limitations
Bibliography
About VacZine Analytics
Disclaimer
Slide number = 77
Model worksheet number 90 - 100

【免責事項】
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ 渡航者向けデング熱ワクチンの世界市場(MarketVIEW: Dengue traveler vaccines)]についてメールでお問い合わせはこちらでお願いします。


◆H&Iグローバルリサーチのお客様(例)◆